Abstract: Provided herein are methods for the prevention and treatment of cardiovascular diseases and disorders in a subject diagnosed as having suffered a cerebrovascular injury by administering agents that contain or induce the expression of microRNA-126.

Abstract: The present invention discloses daclatasvir (DCV) for use in the treatment and/or prevention of cancer, preferably lung cancer and/or prostate cancer, more preferably enzalutamide-resistant prostate cancer.

Abstract: A method for selecting a medical device for use in the performance of a medical procedure. The method comprises acquiring image data relating to an anatomical region of interest of a patient's body and generating a multi-dimensional depiction of the anatomical region of interest using the acquired image data. The method further comprises defining a plurality of points relative to the multi-dimensional depiction, determining one or more measurements based on the defined plurality of points, and then selecting a medical device to be used based on the determined measurements.

Abstract: The present invention relates to the treatment of cancer by irradiation by high energy photons, wherein the cancer has been infused with a heavy metal. The invention further relates to the use of pair-production for increased cancer cell destruction.

Abstract: Provided herein are methods for the prevention and treatment of cardiovascular diseases and disorders in a subject diagnosed as having suffered a cerebrovascular injury by administering agents that contain or induce the expression of microRNA-126.

Abstract: The disclosure provides methods of preventing or treating heart failure in a mammalian subject, reducing risk factors associated with heart failure, and/or reducing the likelihood or seventy of heart failure. The disclosure also provides methods of preventing, or treating LV remodeling in a mammalian subject, and/or reducing the likelihood or severity of LV remodeling. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide. In some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to reduce levels of C-reactive protein, tumor necrosis factor alpha, interleukin 6, reactive oxygen species, Nt-pro BNP, and/or cardiac troponin I, and/or reduce expression levels of MLCL AT1 and/or ALCAT 1 in subjects in need thereof.

Abstract: A method for evaluating the placement of a prosthetic heart valve in a structure of interest. The method comprises acquiring one or more depictions of an anatomical region of interest that includes the structure of interest, wherein each depiction shows the structure of interest and/or the blood pool volume of the left ventricular outflow tract (LVOT) of the patient's heart. The method further comprises designating one or more positions in at least one of the one or more depictions wherein each position corresponds to a respective position in the structure of interest at which the prosthetic valve may be placed. The method still further comprises predicting, for each of the one or more designated positions, an amount of blood flow obstruction through the LVOT of the patient's heart that would occur if the prosthetic valve was to be placed at a corresponding position in the structure of interest.

Abstract: Provided herein are methods for the prevention and treatment of cardiovascular diseases and disorders in a subject diagnosed as having suffered a cerebrovascular injury by administering agents that contain or induce the expression of microRNA-126.

Abstract: An endoscopic catheter assembly including a catheter portion is disclosed. The catheter portion includes a proximal portion and a distal portion. The catheter portion includes a tube-shaped body defining a passage extending there-through.

Abstract: Without limitation, a method for preventing and/or treating neuropathic pain in a subject/patient comprising administering a therapeutically effective amount of exosomes derived and isolated from mammalian cells to the subject/patient and a method of treating cancer in a subject/patient in need thereof, comprises administering a combination comprising a therapeutically effective amount of exosomes derived and isolated from mammalian cells and a chemotherapeutic agent.

Abstract: The present disclosure provides methods for creation, validation and application of a polygenic response predictor (PRP) score which can identify and/or predict beta-blocker survival benefit in heart failure. In one aspect, provided herein are systems and methods for identifying, diagnosing, and treating heart failure patients of European descent who are likely to respond to beta-blocker treatment.

Abstract: A method of detecting intravascular volume depletion in a patient during a hemodialysis session includes measuring venous drip pressure for the patient. With a computer-driven analyzer, the method further includes analyzing the venous drip pressure and automatically and continuously determining a venous access pressure in proximity to a location of needle insertion into a vascular access site of the patient, wherein changes in venous access pressure are representative of changes in intravascular blood pressure. Using the analyzer, the method further includes comparing the venous access pressure to a standard and, if the venous access pressure is outside of a defined range of the standard, determining with the analyzer that the patient is experiencing intravascular volume depletion during the hemodialysis session.

Abstract: A system and method for testing an effect of light exposure on a skin sample include a solar simulator arranged to administer a combination of visible light (VL) and long wavelength ultraviolet radiation (UVA1) to the skin sample. The solar simulator includes a lamp for generating a light beam and at least one customized filter for receiving the light beam and emitting a VL+UVA1 spectral output having a wavelength range of 370-700 nm for irradiating the skin sample.

Abstract: A system for characterization of a brain tissue sample includes a laser having an excitation fiber and a probe coupled to the excitation fiber for irradiating the brain tissue sample with light at an excitation wavelength. The probe further includes a plurality of return fibers for receiving light scattered from the brain tissue sample, wherein each return fiber includes a microfilter that permits light to pass for a different, spaced apart marker region. A Raman spectrometer is in communication with the plurality of return fibers, and a processor is in communication with the Raman spectrometer for analyzing Raman spectra within the marker regions to identify a tissue type of the brain tissue sample as one of normal white matter brain tissue, normal grey matter brain tissue, brain tumor tissue, infiltrating tumor tissue, and necrotic tissue.

Abstract: Without limitation, a method for preventing and/or treating neuropathic pain in a subject/patient comprising administering a therapeutically effective amount of exosomes derived and isolated from mammalian cells to the subject/patient and a method of treating cancer in a subject/patient in need thereof, comprises administering a combination comprising a therapeutically effective amount of exosomes derived and isolated from mammalian cells and a chemotherapeutic agent.

Abstract: A method and a system are provided for detecting a condition indicative of a dislodged needle in a hemodialysis procedure. A venous return pressure for a patient undergoing dialysis is measured. The venous return pressure is analyzed via a controller, and an intravascular blood pressure in proximity to a location of needle insertion into the patient is derived. A lower limit is calculated as a function of the intravascular blood pressure via the controller. An average of the venous return pressure is calculated via the controller during a predetermined time window. The average is compared to the lower limit via the controller, and if the average is within a specified range of the lower limit, the controller determines that a condition indicative of a dislodged needle is present.

Abstract: Some embodiments comprise a method and kit for the treatment and prevention of stroke by administering a therapeutically effective combination of mammalian exosomes and/or microvesicles, collectively referred to as extracellular vesicles, and Tissue Plasminogen Activator (tPA), and/or a thrombectomy procedure, to a subject in need thereof. Some embodiments comprise a method and kit for the treatment and prevention of cerebrovascular injury caused by a stroke by administering a therapeutically effective combination of mammalian exosomes, Tissue Plasminogen Activator (tPA), and/or a thrombectomy procedure, to a subject in need thereof. Some embodiments also comprise the administration a therapeutically effective amount of a combination comprising mammalian exosomes and Tissue Plasminogen Activator (tPA) to a subject in need thereof; the mammalian exosomes containing one or more microRNAs selected from miR-19a, miR-21, and miR-146a.

Abstract: Disclosed delivery catheters have a three-dimensional curvature that facilitates reaching the RAA from the inferior vena cava, positioning the distal end of the catheter generally parallel to the plane of the pericardial space at the puncture location within the RAA, orienting the puncturing device in a direction that avoids the right coronary artery, aorta, pulmonary artery, and other structures to prevent bystander injury to such structures, and provides sufficient rigidity to puncture through a wall of the RAA into the pericardial space.

Abstract: A method for treating diastolic heart failure is provided including identifying a subject having diastolic heart failure and administering a therapeutically effective amount of a galectin-3 inhibitor to the subject to at least partially alleviate a symptom of diastolic heart failure.